Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
about
Human immunodeficiency virus-associated pulmonary arterial hypertensionRole of endothelin in uteroplacental circulation and fetal vascular functionSildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorAssociation of CYP2C9*2 with bosentan-induced liver injury.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.New pharmacotherapy options for pulmonary arterial hypertension.Pharmacological treatment of HIV-associated pulmonary hypertension.Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.Pulmonary Arterial Hypertension: Combination Therapy in Practice.
P2860
Q26824782-29ABA42D-B7DD-4AF0-B7A6-1288A8F4F2EAQ26828020-FC86454D-B8C2-4280-A96F-34DE368D962EQ35290066-4E0226F0-1890-4518-B9A0-1DF49AF3948EQ37325319-59D82CB6-201B-44FB-B346-E6FC10A3A0EBQ38164816-0209FE40-7083-4A7A-89E7-001B9673C2A5Q38183877-4F0369EC-6412-43A7-8C60-ECCFEA2960DEQ38271119-04955AA5-0ED1-49A8-BB65-003C3B66396AQ38325919-F8434EB4-DE6E-4B7E-A417-8744C3C5274DQ38569940-2FE8390B-D1E7-487D-9E86-91F11B670032Q38728500-B4E7DA94-5406-4114-9EAB-41FF3CD480D1Q38731518-BFA08E2D-FD58-4D23-96D6-567595501655Q39265331-ABBB3E84-FC83-447D-B979-C0BA2DFA7078Q44288514-623A346A-7E0A-4E7F-8AF9-B88E50EA973DQ52364945-72992FE1-2388-489A-B543-B6182DAB0081
P2860
Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@en
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@nl
type
label
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@en
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@nl
prefLabel
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@en
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@nl
P2093
P2860
P356
P1476
Clinical pharmacokinetics and ...... lmonary arterial hypertension.
@en
P2093
Christopher Dufton
Hunter Gillies
Jean Regnault
Julia Zack
Jürgen Venitz
Martine Allard
P2860
P304
P356
10.1177/0091270011423662
P577
2011-12-28T00:00:00Z